Blueprint Medicines Corporation (BPMC) Comparison with companies in other sectors?

Blueprint Medicines Corporation has a share price of 64.67M. You can analyze Blueprint Medicines Corporation (BPMC) competitors across different market sectors through stock heatmaps.

What are BPMC's NET and operating margins?

Blueprint Medicines Corporation (BPMC) operating margin is around -0.31, and net profit margin is approximately -0.28 as of the latest reports.

In what way does BPMC's earnings per share (EPS) trend reflect its financial momentum?

Blueprint Medicines Corporation (BPMC) EPS is -2.51 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Blueprint Medicines Corporation is -51.58, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Blueprint Medicines Corporation?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Blueprint Medicines Corporation like P/E which is -52.87, P/B which is 24.07, and PEG which is 0.38. Compare them with sector averages to evaluate if the stock is priced fairly.

Blueprint Medicines Corporation

BPMC•NASDAQ

Healthcare

Biotechnology

$129.46

$0.18(0.14%)

Fundamental Analysis of Blueprint Medicines Corporation (BPMC)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-2.51

P/E Ratio

-51.58

ROE

-0.49%

Net Margin

-0.28%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$8.36B

Shares OutstandingTotal number of shares issued

$64.67M

Book Value/ShareNet worth per share

$5.38

Revenue/ShareAnnual revenue per share

$8.84

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-2.51

Net MarginNet income as percentage of revenue

-27.70%

Operating MarginOperating income as percentage of revenue

-31.01%

ROEReturn on shareholders' equity

-48.89%

ROAReturn on total assets

-13.03%

ROCEReturn on capital employed

-18.44%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-2.37

Cash/ShareCash and equivalents per share

$9.06

FCF YieldFree cash flow as percentage of market cap

-1.80%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BPMCFinancial Ratios Analysis details for BPMC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BPMCSector Benchmarking details for BPMC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Blueprint Medicines Corporation Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Blueprint Medicines Corporation. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Blueprint Medicines Corporation's unique business strengths and challenges.

Key Financial Metrics for Blueprint Medicines Corporation

For Blueprint Medicines Corporation, essential financial indicators include EPS -2.51, PE -51.58, and ROE -0.49. These key ratios reveal insights into Blueprint Medicines Corporation's profitability, valuation, and operational health. Understanding these metrics enables you to compare Blueprint Medicines Corporation with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Blueprint Medicines Corporation

Metrics like Net Margin -27.70% and ROA -13.03% shed light on how well Blueprint Medicines Corporation is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Blueprint Medicines Corporation can sustain its operations and continue growing in the future.

Valuation and Market Position of Blueprint Medicines Corporation

Using ratios such as P/B Ratio 24.07 and PEG Ratio 0.38, investors can assess whether Blueprint Medicines Corporation is appropriately valued based on its financials and growth potential. These figures, combined with Blueprint Medicines Corporation's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Blueprint Medicines Corporation

Financial health indicators, such as Debt/Equity Ratio 0.36 and Cash Flow $-2.37, provide a snapshot of Blueprint Medicines Corporation's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Blueprint Medicines Corporation, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Blueprint Medicines Corporation

Investing in Blueprint Medicines Corporation based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Blueprint Medicines Corporation focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;